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Abstract
In structural studies, the retrovirus capsid interdomain linker region has been shown as a flexible connector between the CA N-terminal
domain and its C-terminal domain. To analyze the function of the linker region, we have examined the effects of three Moloney murine
leukemia virus (M-MuLV) capsid linker mutations/variations in vivo, in the context of the full-length M-MuLV structural precursor protein
(PrGag). Two mutations, A1SP and A5SP, respectively, inserted three and seven additional codons within the linker region to test the effects
of increased linker lengths. The third variant, HIV/Mo, represented a chimeric HIV-1/M-MuLV PrGag protein, fused at the linker region.
When expressed in cells, the three variants reduced the efficiency of virus particle assembly, with PrGag proteins and particles accumulating
at the cellular plasma membranes. Although PrGag recognition of viral RNA was not impaired, the capsid linker variant particles were
abnormal, with decreased stabilities, anomalous densities, and aberrant multiple lobed and tubular morphologies. Additionally, rather than
crosslinking as PrGag dimers, particle-associated A1SP, A5SP, and HIV/Mo proteins showed an increased propensity to crosslink as trimers.
Our results suggest that a wild-type retrovirus capsid linker region is required for the proper alignment of capsid protein domains.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Structural studies on the capsid (CA) protein of several
retroviruses have revealed that it is composed of an N-
terminal domain (NTD) and a C-terminal domain (CTD),
which includes the conserved major homology region
(MHR; Berthet-Colominas et al., 1999; Campos-Olivas et
al., 2000; Gamble et al., 1996; Gitti et al., 1996; Jin et al.,
1999; Khorasanizadeh et al., 1999; Kingston et al., 2000;
Momany et al., 1996). The CA NTD and CTD are separated
by an apparently flexible linker region (Fig. 1) that allows
the two domains to orient independently in solution, but
which serves an unknown function in vivo (Berthet-Colo-
minas et al., 1999; Campos-Olivas et al., 2000; Gamble et
al., 1996; Gitti et al., 1996; Jin et al., 1999; Khorasanizadeh
et al., 1999; Kingston et al., 2000; Momany et al., 1996).
Retrovirus capsid proteins initially are synthesized as parts
of the Gag precursor (PrGag) proteins, which also include
matrix (MA), nucleocapsid (NC), and other polypeptides
involved in virus assembly (Swanstrom and Wills, 1997).
Processing of PrGag proteins by the viral protease (PR)
releases the individual MA, CA, and NC Gag proteins and
is a necessary step in the conversion of immature to mature,
infectious retrovirus particles (Swanstrom and Wills, 1997).
Consequently, capsid proteins and their constituent domains
may serve different roles in immature versus mature virus
forms.
The roles performed by capsid proteins of retroviruses
such as HIV, Moloney murine leukemia virus (M-MuLV),
and the avian Rous sarcoma virus (RSV) have been ex-
plored largely through molecular genetic investigations
(Alin and Goff, 1996; Borsetti et al., 2001; Bowzard et al.,
2001; Craven et al., 1995; Mammano et al., 1994; McDer-
mott et al., 1996, 2000a; Schwartzberg et al., 1984; Swan-
strom and Wills, 1997; Tang et al., 2001; von Schwedler et
al., 1998; Wang and Barklis, 1993). Mutations in the coding
regions for the CA NTD and CTD of HIV, M-MuLV, and
RSV have yielded defects in virus assembly, particle sta-
bility and morphogenesis, and reverse transcription. Inter-
estingly, suppressor mutations for several lethal mutations
in the RSV MHR have been mapped to the capsid NTD
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(Bowzard et al., 2001), indicating a functional communica-
tion between the two domains.
Despite the genetic demonstration of a functional inter-
action between capsid N-terminal and C-terminal domains,
the nature of the interaction and the potential role of the
linker region in regulation of interdomain communication
are unclear. We now report the analysis of M-MuLV capsid
linker region mutants and variants designed to probe the
function of these interdomain sequences. To probe linker
length requirements, linker regions with added residues
have been tested, and to examine linker effects on heterol-
ogous capsid domains, a chimeric HIV/M-MuLV Gag pro-
tein has been characterized. Our results indicate that pertur-
bation of the linker region is lethal to M-MuLV, reducing
particle release and causing an accumulation PrGag proteins
at plasma membranes. Although mutant particles encapsi-
dated M-MuLV genomic RNA, they had aberrant densities
and stabilities and showed lobed, elongated, and tubular
morphologies, reminiscent of late assembly domain gag
mutants (Demirov et al. 2002a, 2002b; Garrus et al., 2001;
Kikonyogo et al., 2001; Patnaik et al., 2000; Strack et al.,
2000; VerPlank et al., 2001; Yuan et al., 1999, 2000).
Addition of extra residues in the linker region also shifted
PrGag crosslink profiles from dimers (Hansen and Barklis,
1995; McDermott et al., 1996, 2000b) to trimers. Our results
indicate that the linker region is important in the control of
Gag protein interactions.
Results
Linker region effects on particle release
In structures available for mammalian and avian retrovi-
rus capsid proteins (Berthet-Colominas et al., 1999; Cam-
pos-Olivas et al., 2000; Gamble et al., 1996, 1997; Gitti et
al., 1996; Jin et al., 1999; Khorasanizadeh et al., 1999;
Kingston et al., 2000; Momany et al., 1996; Petroupoulos,
1997; Tang et al., 2002), as well as secondary structure
predictions of CA NTD–CTD juncture regions (Baldi et al.,
1999; Jones, 1999; McGuffin, 2000; Raghava, 2000), inter-
domain linker regions of 6–13 residues have been identified
(see Fig. 1). While all of the listed observed or predicted
linkers have proline residues near their N-termini,
M-MuLV, HIV-1, and HIV-2 also share the sequence (S/
N)PT(N/S)(I/L) in this region. This shared sequence corre-
sponds to HIV-1 gag codons 278–282 and M-MuLV gag
codons 347–351. To probe the function of the M-MuLV
capsid linker region in the context of the wild-type (WT)
PrGag protein, several linker region variants were con-
structed. These included constructs A1SP and A5SP, which
were designed to lengthen the linker region by three (ASP)
and seven (AAAAASP) residues, respectively (Fig. 2). We
also constructed the HIV/Mo PrGag chimera, which fuses
the HIV-1 and M-MuLV linker region SPT sequences so as
Fig. 1. Alignment of retrovirus capsid linker sequences. Capsid linker
sequences located just upstream of retrovirus major homology regions
(MHR) were aligned for Moloney murine leukemia virus (M-MuuLV),
HIV-1 and -2, human T cell leukemia virus (HTLV1), mouse mammary
tumor virus (MMTV), Mason Pfizer monkey virus (MPMV), and Rous
sarcoma virus (RSV). Observed and predicted (Baldi et al., 1999; Berthet-
Colominas et al., 1999; Campos-Olivas et al., 2000; Gamble et al., 1996,
1997; Gitti et al., 1996; Jin et al., 1999; Jones et al., 1999; Khorasanizadeh
et al., 1999; Kingston et al., 2000; McGuffin et al., 2000; Momany et al.,
1996; Petroupoulos, 1997; Raghava, 2000) capsid N-terminal domain helix
7 sequences are as shown, and intervening linkers of 6–13 residues are
aligned. As shown, the M-MuLV, HIV-1, and HIV-2 sequences share the
sequence (S/N)PT(N/S)(I/L) in this region.
Fig. 2. Recombinant viral constructs. The observed and predicted HIV-1
and M-MuLV capsid (CA) linker regions between the CA N-terminal
domain (NTD) and C-terminal domain (CTD) are adjacent to the CA major
homology region (MHR). Predicted linker sequences corresponding to
HIV-1 (HXB2) gag codons 278–284 and M-MuLV gag codons 347–356
are shown with their SPT sequences aligned as in Fig. 1. To examine the
functions of the linker region, several Gag protein expression vectors were
constructed. The WT (pXM-WT) construct expresses the wild-type M-
MuLV Gag protein from an adenovirus late promoter in a protease-minus
(PR) setting. The insertion mutation constructs A1SP (pXM-
ins348A1SP) and A5SP (pXM-ins348A5SP) encode proteins with three
and seven residue insertions after gag codon 348 corresponding to ASP and
AAAAASP, respectively. The chimeric HIV/Mo construct (pXM-HIV/
Mo) encodes a fusion protein translated from HIV-1 gag codons 1–278 and
M-MuLV gag codons 348–538. The predicted HIV/Mo protein is expected
to be approximately 52 kDa and composed of the HIV-1 matrix domain
and capsid NTD, a chimeric linker region, and the M-MuLV CTD and
complete nucleocapsid domain. Protease-plus versions of the M-MuLV
constructs are designated WT PR, A1SP PR, and A5SP PR and are
encoded by pXM-gpe-type constructs which express M-MuLV gag, pol,
and env genes.
167B. Arvidson et al. / Virology 308 (2003) 166–177
to encode a chimera composed of the HIV-1 matrix and
NTD, plus the M-MuLV CTD and nucleocapsid (Fig. 2).
Expression of WT, A1SP, A5SP, and HIV/Mo constructs
in transfected 293T cells yielded major cellular PrGag
bands of the expected sizes (Fig. 3, lanes B, D, F, H). In
particular, the major WT, A1SP, and A5SP PrGag proteins
migrated at approximately 65 kDa (Fig. 3B, 3D and 3F),
while minor A1S1- and A5SP-specific bands—possibly rep-
resenting breakdown products—migrated at about 50 kDa.
The chimeric HIV/Mo construct showed a predominant
PrGag band at 52 kDa (Fig. 3, lane H), consistent with its
predicted size, but also showed a putative breakdown prod-
uct at about 45 kDa and a variable band at about 60 kDa. To
monitor the levels of extracellular, particle-associated Gag
proteins, media samples from transfected cells were centri-
fuged through sucrose cushions, and Gag proteins in pel-
leted material (Fig. 3, lanes A, C, E and G) were detected by
immunoblotting. Since we used matched media pellet and
cell samples, it was possible to compare particle release
levels of our different constructs by comparison of virus to
cell Gag protein levels. As illustrated, while A1SP, A5SP,
and HIV/Mo Gag proteins were detected in media pellet
samples, the virus:cell Gag ratios were reduced somewhat
relative to WT, suggesting an impairment in particle assem-
bly or release for the variants. Total densitometric quanti-
tation of all virus and cell Gag bands from several indepen-
dent transfections indicated release levels (relative to WT)
of 49  8, 38  7, and 50  18 for the A1SP, A5SP, and
HIV/Mo constructs, respectively. Although these release
reductions were relatively small, the mutant release levels
were close to what we have observed using the same meth-
ods for M-MuLV late (p12) domain assembly mutants
(Yuan et al., 1999, 2000). Thus, we believe our experimen-
tal system gives a conservative estimate as to the impair-
ment of particle release for the linker region mutants.
Conceivably, reduced Gag protein release levels could
have been a consequence of reduced membrane binding for
Gag protein variants. In this regard, subcellular fraction-
ation (Hansen et al., 1993) experiments demonstrated nor-
mal membrane to cytosol distributions for the A1SP, A5SP,
and HIV/Mo proteins (data not shown). However, because
membrane fractions can be contaminated with membrane-
free PrGag oligomers, a complementary localization assay
was employed. As an alternative way to evaluate Gag sub-
cellular distributions for the WT, A1SP, and A5SP proteins,
indirect immunofluorescence localization studies were per-
formed using an anti-M-MuLV p12 primary antibody
(Chesebro et al., 1983; Hansen et al., 1993; epitope not
present on HIV/Mo proteins). As observed previously
(Barklis et al., 1997; Hansen et al., 1993), wild-type PrGag
proteins stained a distinct punctate pattern, with a bright
haze of fluorescence in a perinuclear region (Figs. 4A and
B). Although A1SP and A5SP proteins also often showed
perinuclear staining (Figs. 4C–F), the WT punctate appear-
ance was replaced by a patchy haze of fluorescence for the
two variants (Figs. 4C–F). In most cases, Gag-staining
A1SP and A5SP cells had increased staining at cell edges,
suggesting an accumulation of Gag proteins at plasma mem-
branes. Tabulation of staining patterns (Fig. 4 legend) indi-
cated that peripheral staining was observed on 2 to 2.5 times
more A1SP and A5SP cells than WT cells. Although such
tabulation is, at least in part, subjective, these results are
consistent with the notion that reduced extracellular levels
of capsid linker variants were caused by the impaired re-
lease of plasma membrane-associated Gag proteins.
Characterization of virus particles
Although A1SP, A5SP, and HIV/Mo proteins appeared
to assemble and release particles, the nature of these parti-
cles was uncertain. Because immature M-MuLV particles
have densities of 1.15–1.17 g/ml (Jones et al., 1990, Hansen
et al., 1990), we initially subjected pelleted (165S) media
samples to 20–50% sucrose density gradient fractionation.
With WT particles, we observed the anticipated 1.15–1.17
g/ml density peak, along with some higher density material
(data not shown). However, the three Gag variants showed
anomalous fractionation patterns: A1SP particles were
slightly more dense than WT; A5SP particles gave a 1.15–
1.17 g/ml peak, but showed a wider spread of particle
densities than WT; and HIV/Mo particles appeared to be
Fig. 3. Virus particle release. Cell lysate (C) and pelleted media (V)
samples from 293T cells transfected with the indicated constructs were
collected, fractionated by SDS–PAGE, and subjected to immunodetection
for Gag proteins using an anti-M-MuLV CA (Hy187) antibody. Note that
while major PrGag bands migrated at the predicted 65-kDa (WT, A1SP,
A5SP) and 52-kDa (HIV/Mo) sizes, subsidiary bands were observed at 50
kDa for the A1SP and A5SP constructs and at 60 and 45 kDa for the
HIV/Mo construct. Note also that the minor bands at 30 kDa in lanes B, D,
F, and more faintly in H correspond to a cross-reactive protein present in
mock-transfected cells. Gag protein release levels, relative to WT release
levels (100%), were determined from ratios of total released versus
cellular Gag protein levels and were quantitated from densitometrically
scanned unsaturated blots from several independent experiments. Release
levels were as follows: A1SP, 49 8% (N 3); A5SP, 38 7% (N 3);
HIV/Mo, 50  18% (N  2).
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considerably more dense than normal M-MuLV virions
(data not shown). Capsid linker variant particles also ap-
peared to differ from WT in their sensitivities to non-ionic
detergent (Triton X-100; TX100) treatment (Fig. 5). As
observed previously (Hansen et al., 1993), Triton X-100
treatment of WT particles somewhat increased the amount
of soluble Gag protein. On A1SP and HIV/Mo particles, the
detergent appeared to show a slightly increased ability to
solubilize Gag proteins, while treatment of A5SP particles
resulted in the solubilization of greater than half of the total
Gag protein (Fig. 5).
While density gradient and detergent treatment experi-
ments implied that A1SP, A5SP, and HIV/Mo Gag protein–
protein contacts were compromised, it was of interest to
examine Gag protein–RNA interactions. Thus, we exam-
ined the abilities of WT and capsid linker variant proteins to
encapsidate viral RNAs. For this purpose, Gag expression
constructs were cotransfected into cells with the MP10
construct (Barklis et al., 1986; Mougel et al., 1996). MP10
expresses full-length (genomic) and spliced recombinant
M-MuLV RNAs, which can be measured simultaneously
with an antisense RNase protection probe (Barklis et al.,
1986; Mougel et al., 1996). As illustrated in Fig. 6, both
genomic and spliced MP10 RNAs were detected in cells
transfected with MP10 alone or with MP10 in the presence
of Gag protein expression constructs (Fig. 6, lanes C–G). As
expected, the RNAs were not detected in pelleted media
samples from cells transfected with MP10 alone (Fig. 6,
lane K), whereas WT particles preferentially packaged full-
length MP10 transcripts (Fig. 6, lane H). Interestingly,
A1SP, A5SP, and HIV/Mo particles also encapsidated
MP10 RNAs, with an apparent preference for genomic
versus spliced transcripts (Fig. 6, lanes I, J and L). Densi-
tometric quantitation of particle-associated MP10 RNAs
yielded roughly equivalent genomic:spliced RNA ratios
(Fig. 6 legend), indicating similar selectivities for the WT
and variant proteins. After normalization for Gag protein
content, genomic MP10 RNA levels in A1SP, A5SP, and
HIV/Mo particles were somewhat reduced (54–84%; Fig. 6
legend) relative to WT particles, suggesting a slight reduc-
Fig. 5. Virus particle stabilities. Extracellular particles assembled by the
indicated Gag proteins were either untreated () or treated () with 0.5%
Triton X-100 and incubated on ice 30 min. Following incubations, samples
were centrifuged at 100,000 g for 30 min at 4°C. Pellet (black) and
supernatant (super; gray) samples were collected and fractionated by SDS–
PAGE, after which PrGag proteins were detected by immunoblotting and
quantitated densitometrically. Bar graphs depict percentages of total PrGag
protein levels in supernatant or pellet fractions for each sedimentation
experiment.
Fig. 4. Immunofluorescent localization of Gag proteins. Three days post-
transfection with the indicated constructs, Cos7 cells were fixed, perme-
abilized, and processed for immunolocalization of PrGag proteins using a
primary anti-M-MuLV p12 antibody (Hy548) and a rhodamine-conjugated
secondary antibody. Gag proteins expressed from all three constructs
showed evidence of a perinuclear localization, but WT proteins also
showed a punctate localization pattern (A, B), while A1SP (C, D) and
A5SP (E, F) proteins showed heterogeneous, sometimes patchy, localiza-
tion patterns, often with increased fluorescence at cell peripheries. Percent-
ages of fluorescent cells showing perinuclear, punctate, or peripheral stain-
ing were as follows: perinuclear staining, WT72%, A1SP58%,
A5SP67%; punctate staining, WT69%, A1SP32%, A5SP19%; in-
creased peripheral staining, WT31%, A1SP60%, A5SP78%. The
size bar at the bottom right corresponds to 40 m.
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tion in encapsidation efficiencies. However, our results in-
dicate that pertubation of the capsid linker region and re-
placement of M-MuLV N-terminal PrGag sequences with
those of HIV-1 did not have a major effect on encapsidation.
Since capsid linker variant proteins packaged viral RNAs
with near normal efficiencies and selectivities, it seemed
possible that particles assembled by these proteins might
have normal morphologies. This possibility was examined
through electron microscopic (EM) analysis of transfected
cells, and our observations are summarized in Table 1. As
the table indicates, viral particles and structures were ob-
served at plasma membranes and in extracellular areas from
cells transfected with each of the constructs. With WT
transfections, the majority (71%) of observed particles were
classified as normal in appearance, meaning that they were
circular in projection, with 120- to 180-nm diameters and an
electron-dense ring adjacent to the particle surface: exam-
ples are shown in Figs. 7A and B. A noteworthy feature
with WT transfections was that only a third of the particles
appeared to have been caught in the process of assembly or
release (Table 1), implying that WT particle assembly at the
plasma membrane was relatively rapid.
In contrast with WT transfections, nearly half of the viral
structures observed from A1SP, A5SP, and HIV/Mo trans-
fected cells appeared to be in the act of assembly (Table 1).
These observations, exemplified in Figs. 7C, E and G,
suggest that plasma membrane release of capsid linker vari-
ant particles occurred slowly and may explain the cell sur-
face accumulation of A1SP and A5SP Gag proteins ob-
served in immunofluorescence localization studies (Fig. 4).
In addition to showing increased numbers of assembling
structures, the morphologies of capsid linker variant parti-
cles were abnormal. Many (44%) of the A1SP particles
were classified as irregular, with multiple lobes, elongated
shapes, or crescents of electron density (Table 1). However,
a high percentage (42%) were elongated tubes that were
lined with tracks of electron density (Fig. 7D), reminiscent
of the appearance of gag late assembly domain mutants
(Demirov et al. 2002a, 2002b; Garrus et al., 2001;
Kikonyogo et al., 2001; Patnaik et al., 2000; Strack et al.,
2000; VerPlank et al., 2001; Yuan et al., 1999, 2000).
Similar results were obtained with A5SP, with the distinc-
tion that higher percentages of tubes were seen (Table 1),
and the tubes were more heterogeneous in appearance (Figs.
7E and F). The HIV/Mo particles differed from their WT,
A1SP, and A5SP counterparts. While very few tube forms
were noted, abnormal elongated and lobed particles pre-
dominated (Table 1). Frequent particles with incomplete
crescents of electron density were evident, as were particles
with multiple lobes (Figs. 7G and H). Thus, the general
appearance of capsid linker variant particles suggested that
improper interprotein contacts were made at the cell surface.
Using a cell culture system, it is difficult to assess exactly
how PrGag contacts differ between WT, A1SP, A5SP, and
HIV/Mo proteins. However, we previously have demon-
Table 1
Classification of particle morphologies
Construct Assembling Normal Irregular Tube
WT 33 71 20 9
A1SP 46 14 44 42
A5SP 47 6 43 51
HIV/Mo 49 26 70 4
Note. Virus-like particles were imaged by EM after processing of 293T
cells transfected with the indicated constructs. Percentages of assembling
particles and of particles with normal, irregular, and tube morphologies
were counted from a total of 70 (WT), 166 (A1SP), 122 (A5SP), and 387
(HIV/Mo) particles. Assembling particles were defined as particles with
evident plasma membrane attachments, and both assembling and released
particles were counted in the calculation of normal, irregular, and tube
percentages. Normal particles were defined operationally as 120- to 180-
nm-diameter particles with a characteristic circle of electron density adja-
cent to the particle surface. The irregular particle classsification included
off-sized particles; long oval or indented particles; particles with multiple
lobes; and particles with incomplete crescents of electron density. Tubes
were defined as having an axial ratio of 2, a width of 100–200 nm, and
electron-dense tracks adjacent to tube surfaces.
Fig. 6. Viral RNA encapsidation. Triplicate 10-cm plates of 293T cells
were transfected with a construct expressing the packagable M-MuLV
vector MP10 in the absence (lanes F and K) or the presence of Gag protein
expression constructs WT (lanes C and H), A1SP (lanes D and I), A5SP
(lanes E and J), and HIV/Mo (lanes G and L). Three days posttransfection,
total cellular RNA samples were extracted from cells, and pelleted extra-
cellular particle (virus) samples were collected for RNA isolation and Gag
protein detection by immunoblotting. Cell (lanes C–G) and viral (lanes
H–L) MP10 RNAs were detected by RNase protection with a 274–nt
antisense probe (lane A), which protects a viral genomic RNA fragment of
214 nt, and a spliced RNA fragment of 205 nt. In the absence of MP10
RNA, the antisense probe is digested during the protection protocol (lane
B). Quantitation of MP10 genomic and spliced RNAs in virus samples
yielded the following genomic:spliced RNA ratios: WT, 1.19; A1SP, 1.58;
A5SP, 1.60; HIV/Mo, 1.34. Levels of particle-associated genomic MP10
RNA, normalized for particle-associated Gag protein levels, were as fol-
lows: WT, 1.0; A1SP, 0.78; A5SP, 0.54%; HIV/Mo, 0.82%.
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strated that Gag protein contacts in virus particles can
be probed with membrane-permeant, cysteine-specific
crosslinking agents such as bis-maleimidohexane (BMH;
Hansen and Barklis, 1995; McDermott et al., 1996, 2000a).
In particular, we have shown that PrGag domains in imma-
ture M-MuLV particles are preferentially crosslinked at
nucleocapsid domain cysteines to yield dimers, implicating
PrGag dimers as particle building blocks (Hansen and Bark-
lis, 1995; McDermott et al., 2000b). With this backround,
we decided to probe capsid linker variant particles by BMH
crosslinking. To do so, particles were mock- or BMH-
treated, and PrGag crosslink products were detected after
electrophoresis and immunoblotting (Figs. 8 and 9). Our
results with the WT construct (Fig. 8, lanes A and B; Fig. 9,
lanes A and B) duplicated those observed previously in that
PrGag dimers were the major crosslink forms. In contrast,
A1SP PrGag proteins crosslinked to yield dimers migrating
at about 126 kDa and trimers at about 162 kDa (Fig. 8C),
while A5SP crosslink products were skewed even more
toward trimer forms (Fig. 8E). Analysis of HIV/Mo
crosslink profiles was more complicated, as a consequence
of the greater number of subsidiary crosslink products (Fig.
9, lanes C and D). Nevertheless, crosslink products were
clearly evident in both the dimer and trimer regions (Fig. 9,
lane C), as we observed with A1SP. These crosslink profiles
indicate that capsid linker sequence alterations resulted in
an increase in PrGag trimer versus dimer products.
Fig. 7. Virus particle morphologies. Three days posttransfection with the indicated constructs, 293T cells were processed for EM as described under Materials
and Methods. Images of cells transfected with WT (A and B), A1SP (C and D), A5SP (E and F), and HIV/Mo (G and H) constructs were collected
electronically at original magnifications of 2810–11,290 and are shown with 200-nm bars. Observed particle morphologies are tabulated in Table 1.
Fig. 8. Crosslinking of spacer mutant Gag proteins. Pelleted extracellular
particles from 293T cells transfected with the indicated constructs were
mock-treated () or treated () with the crosslinker bis-maleimidohexane
(BMH) prior to electrophoresis and immunodetection of Gag proteins. The
indicated molecular weight size designations were calculated by compari-
sion of mobilities with molecular weight size markers.
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Linker region effects in replication-competent constructs
The above studies on WT, A1SP, A5SP, and HIV/Mo
constructs in a PR context revealed significant defects for
the linker region variants. Nevertheless, investigations were
undertaken with A1SP and A5SP to determine their effects
in replication-competent constructs. One approach was to
express the mutations in M-MuLV proviral constructs
(pMov9-1-A1SP and pMov9-1-A5SP), stably transfected
into Rat1 cells. However, while stable A1SP and A5SP Gag
protein-expressing cell clones were isolated, particle release
was minimal, no infectious virions were isolated, and we
were unable to obtain viable, viral revertants (data not
shown). A second approach was to transfer the mutations to
a transient transfection vector (pXMgpe; McDermott et al.,
2000a), which permits expression of M-MuLV gag, pol,
and env genes and mobilization of MP10 proviruses. To test
linker region effects in this system, pXMgpe variants WT
PR, A1SP PR, and A5SP PR were cotransfected with
MP10 plasmids into 293T cells. The viruses so generated
were used to infect NIH 3T3 cells in a single round of
infection, and infection events were scored by selection for
MP10 provirus neomycin gene expression. Not surprisingly,
whereas three separate MP10 plus WT PR cotransfections
yielded infectious virus titers of 3275  2165 virus/ml,
MP10 cotransfections with either A1SP PR or A5SP PR
produced no infectious virions.
In an effort to examine the replication defect of the A1SP
PR and A5SP PR constructs, cell lysate and media pellet
(virus) samples from cells transfected with wild-type and
mutant constructs were subjected to Gag protein detection
as described in Fig. 3. With WT PR, A1SP PR, and
A5SP PR cell samples, the expected 65-kDa PrGag bands
were observed, along with bands at 50–55 kDa, which
presumably correspond to partial processing or breakdown
products (Fig. 10, lanes D–F). A quite different result was
obtained with virus samples (Fig. 10, lanes A–C). Whereas
major PrGag and mature 30-kDa capsid bands were ob-
served with WT PR virus samples (Fig. 10, lane A),
particle-associated A1SP PR and A5SP PR PrGag pro-
tein levels were barely detected (Fig. 10, lanes B and C).
Moreover, the A1SP PR and A5SP PR PrGag proteins
were not processed to give mature CA. In comparison with
release levels for the protease-minus A1SP and A5SP con-
structs (Fig. 3), A1SP PR and A5SP PR particle release
was reduced dramatically. Indeed A1SP PR and A5SP
PR release levels were 7  5 and 5  2% those of WT
PR (Fig. 10 legend), about 5- to 10-fold reduced relative to
the protease-minus versions. Despite this, subcellular frac-
tionation profiles and immunofluorescence localization pat-
terns for the PR and PR capsid linker variants were
comparable (data not shown), suggesting that the same
assembly or release steps were affected. It is noteworthy
Fig. 10. Expression and release of mature Gag proteins. Cell lysate (cells)
and pelleted media (virus) samples from 293T cells transfected with the
indicated constructs were collected, fractionated by SDS–PAGE, and sub-
jected to immunodetection for Gag proteins using anti-M-MuLV CA
(Hy187) antibody. PrGag and mature capsid (CA) bands migrated accord-
ing to their predicted respective 65- and 30-kDa sizes, and subsidiary bands
at 50 kDa also were observed. Total Gag protein release levels, relative to
WT PR release levels (100%), were quantitated from densitometrically
scanned blots from three independent experiments and were 7  5% for
A1SP PR and 5  2% for A5SP PR.
Fig. 9. Crosslinking of chimeric Gag proteins. Pelleted extracellular par-
ticles from 293T cells transfected with the indicated constructs were
mock-treated () or treated () with the crosslinker (BMH) prior to
electrophoresis and immunodetection of Gag proteins. The indicated mo-
lecular weight size designations correspond to the mobilities of molecular
weight marker proteins. Approximate predicted mobilities for WT and
HIV/Mo dimers and for HIV/Mo trimers are indicated by double and triple
arrows, respectively.
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that similar observations have been made concerning the
severity of assembly/release defects in PR versus PR
virions for other retrovirus gag mutations (Huang et al.,
1995).
Discussion
Multiple retrovirus capsid protein structures have dem-
onstrated that the CA NTD and CTD are separated by an
apparently flexible, interdomain linker (Berthet-Colominas
et al., 1999; Campos-Olivas et al., 2000; Gamble et al.,
1996, 1997; Gitti et al., 1996; Jin et al., 1999; Khorasaniza-
deh et al., 1999; Kingston et al., 2000; Momany et al., 1996;
Tang et al., 2002). However, the alignment of CA domains
observed by EM in structures assembled from capsid pro-
teins in vitro (Li et al., 2000; Mayo et al., 2002; McDermott
et al., 2000b) suggests that the linker region does not just
hold the NTD and CTD in close proximity. To examine its
function, we have targetted the predicted M-MuLV capsid
linker region. In this regard, although secondary structure
predictions and alignment algorithms have been used to
identify the M-MuLV CA linker, we cannot exclude the
possibility of NTD or CTD involvement. For our studies,
we added either three (construct A1SP) or seven (construct
A5SP) residues to the predicted linker region. Our rationale
was to test whether the linker might tolerate residue addi-
tions or whether it serves functions which would be more
sensitive to disruption. We also analyzed a chimeric HIV-
1/M-MuLV (HIV/Mo) Gag protein, fused at the linker re-
gion, to examine whether the linker could mediate func-
tional interactions between heterologous CA domains.
Analysis of the A1SP, A5SP, and HIV/Mo variants fa-
vors the interpretation that the wild-type linker sequence
serves a function beyond that of a simple domain connector.
This conclusion is supported by results which showed that
linker variants assembled or released virus particles ineffi-
ciently (Figs. 3 and 10). Immunofluorescence localization
(Fig. 4) and EM (Table 1, Fig. 7) studies indicated that the
PrGag variant proteins appeared to be delivered efficiently
to the plasma membrane, but that assembly at the plasma
membrane was impaired, consistent with a posttransport,
oligomerization defect. The accumulation of linker variant
Gag proteins and viral structures at cell surfaces is rem-
inscent of results with nucleocapsid domain mutants (Wang
et al., 1994; Zhang and Barklis, 1997), and with late assem-
bly domain mutants (Garrus et al., 2001; Kikonyogo et al.,
2001; Patnaik et al., 2000; Strack et al., 2000; VerPlank et
al., 2001; Yuan et al., 1999, 2000). Another similarity with
some late domain mutants (Huang et al., 1995) is that in the
presence of pol and env gene products (in A1SP PR and
A5SP PR), the assembly defects appeared more severe,
perhaps because the protease activity causes the dissolution
of nascent buds (Wills et al., 1994).
In addition to assembling virus particles inefficiently, the
A1SP, A5SP, and HIV/Mo proteins assembled abnormal
particles. Problems did not seem related to Gag protein–
RNA interactions: mutant proteins packaged genomic viral
RNAs efficiently and selectively (Fig. 6), as might be ex-
pected from studies which have implicated NC as the major
encapsidation determinant (Berkowitz et al., 1995; D’Souza
et al., 2001; Zhang and Barklis, 1995). However, A1SP,
A5SP, and HIV/Mo particles showed anomalous densities
and mobilities, while A1SP PR and A5SP PR particles
showed no evidence of PrGag processing to mature CA
(Fig. 10). Particle morphologies for linker variants also
were aberrant. In contrast to the 120- to 180-nm spheres
assembled by WT proteins, mutant structures included in-
dented particles, particles with crescents of electron density,
ovals, multiple lobed structures, and tubes (Table 1, Fig. 7).
Although some of these structures could have arisen as a
consequence of perturbed associations between Gag and
cellular proteins as with late domain mutants (Garrus et al.,
2001; Kikonyogo et al., 2001; Patnaik et al., 2000; Strack et
al., 2000; VerPlank et al., 2001; Yuan et al., 1999, 2000),
we favor an explanation that implicates Gag–Gag interac-
tions. Credence for this interpretation is provided by the fact
that crosslinking of linker variants yielded higher propor-
tions of trimer (versus dimer) PrGag products than WT
proteins (Figs. 8 and 9). Currently, we do not know the
mechanism by which linker variant crosslink profiles are
skewed. It may be that gag NC domains have a natural
preference for trimer formation, but are constrained into a
dimer configuration by wild-type capsid linker region se-
quences. Alternatively, increased linker flexibility may
make it so that NC domains are afforded increased oppor-
tunities to adopt unnatural trimer configurations. It will be
of interest to investigate these and other alternatives on
capsid linker variants in vitro.
Materials and methods
Recombinant DNA constructs
Plasmids WT (pXM-WT), A1SP (pXM-ins348A1SP),
A5SP (pXM-ins348A5SP), and HIV/Mo (pXM-HIV/Mo)
for expression of Gag proteins in the absence of the M-
MuLV protease were based on pXM-2453, which expresses
the M-MuLV Gag protein from the adenovirus major late
promoter and carries an SV40 origin of replication (Hansen
and Barklis, 1995; McDermott et al., 2000a). The WT
plasmid differs from pXM2453 as follows: the 5 EcoRI
cloning site has been eliminated by a fill-in reaction (creat-
ing the sequence GAATTAATTC); gag codon 349 has a
conservative ACC to ACT mutation; and the 3 EcoRI
cloning site immediately follows the last M-MuLV gag
codon with the sequence GAC TAA TGA ATT C, where
GAC is the codon for the last aspartate residue of the
protein. A1SP is identical to WT, except that the sequence
GCT AGC CCC (encoding the three residues ASP) was
inserted between codons 348 and 349. A5SP is identical to
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WT, except that the sequence GCG GCC GCA GCT GCT
AGC CCC (encoding the seven residues AAAAASP) was
inserted between codons 348 and 349. For HIV/Mo, the
pXM-2453 gag EcoRI fragment was replaced with an
EcoRI fragment encoding the HIV/Mo fusion protein. In
this construct, the sequence from the 5 EcoRI site through
the first HIV-1 (HXB2; Ratner et al., 1987) gag codon was
G AAT TCG GCT AGA AGG AGA GAG ATG, and the
sequence from the last M-MuLV gag codon to the 3 EcoRI
site was identical to the sequence in the WT construct. The
HIV/Mo fusion sequence connected the HIV-1 and M-
MuLV capsid spacer regions between HIV gag codon 278
and M-MuLV gag codon 348 with the juncture sequence
CCC/ACT.
Plasmids for expression of the WT and insertion variants
in the presence of M-MuLV pol and env gene products were
WT PR (pXMgpeWT), A1SP PR (pXMgpeA1SP), and
A5SP PR (pXMgpeA5SP). These differ from the previ-
ously described (Hansen and Barklis, 1995; McDermott et
al., 2000b) M-MuLV gag, pol, and env expression construct
in the capsid spacer region sequence changes described
above. The WT and insertion variants also were tested in the
context of the full-length M-MuLV provirus, pMov9-1
(Schnieke et al., 1983). For testing gag mutants in single
round infection assays, the packageable retroviral vector
MP10 (Barklis et al., 1986) was employed. The MP10
proviral construct includes the M-MuLV 5 long terminal
repeat (LTR) to viral nt 566; the M-MuLV splice acceptor
(viral nt 5409–5768); a neomycin cassette; and the 3 end of
M-MuLV, from viral nt 7197 through the 3 LTR (Barklis
et al., 1986): in mammalian cells it can express a neomycin
transcript from either full-length or spliced RNAs. For de-
tection of MP10 transcripts, probes were prepared from the
previously described plasmid SPMLV (Barklis et al., 1986;
Mougel et al., 1996).
Cell culture, transfections, and infections
Cos7 and 293T cell lines were routinely passaged at
37°C in 5% CO2 in Dulbecco’s modified Eagle’s media
(DMEM) supplemented with 10 mM HEPES, pH 7.4, pen-
icillin, and streptomycin, plus 10% fetal calf sera (FCS).
NIH 3T3 and Rat1 cells were passaged similarly, substitut-
ing normal calf sera (NCS) for the FCS. For transfections,
10-cm plates of Cos7 or 293T cells at 50% confluence were
transfected with 16–24 g of plasmid DNA using the cal-
cium phosphate precipitation method (Barklis et al., 1986;
Hansen and Barklis, 1995; McDermott et al., 1996, 2000a;
Wang and Barklis, 1993). For standard protein analysis
experiments, media and washed cell pellets were collected
at 3 days post transfection and stored at80°C prior to use.
Infections followed established protocols (Barklis et al.,
1986; Mougel et al., 1996). Briefly, 10% confluent 10-cm
plates of NIH 3T3 or Rat1 cells were infected for 3 h at
37°C with 2 ml of diluted, filtered (0.2–0.45 m) viral
stocks in the presence of 8 g/ml of polybrene, after which
plates were supplemented with 8 ml of media. Cells infected
with MP10 viruses were selected at 2–3 days postinfection
by splitting them 1:10 to 1:20 into media containing 350
g/ml of G418 (Gibco). G418-resistant colonies were
counted after 7–10 days in selection, and viral titers were
calculated using the formula titer of virus stock (colonies)
(virus dilution factor)(cell split ratio)/(cell proliferation be-
tween infection and selection).
Protein detection, fractionation, and crosslinking
For standard detection of cell- and virus particle-associ-
ated Gag proteins, cell pellet and media samples collected
from transfections were processed for immunoblotting. Cell
samples were processed from 20% of the cell pellet material
by suspension in IPB [20 mM Tris–hydrochloride (pH 7.5),
150 mM NaCl, 1 mM ethylenediaminetetraacetic acid
(EDTA), 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium
deoxycholate, 1.0% Triton X-100, 0.02% sodium azide], 5
min incubation on ice, resuspension, pelleting of insoluble
material at 13,700 g for 15 min at 4°C, and mixing of the
soluble material with 1 volume of 2  sample buffer [12.5
mM Tris–hydrochloride (pH 6.8), 2% SDS, 20% glycerol,
0.25% bromophenol blue] plus 0.1 vol of -mercaptoetha-
nol (-Me). Cell-free media samples were centrifuged
through 2-ml 20% sucrose cushions in phosphate-buffered
saline [PBS; 9.5 mM sodium potassium phosphate (pH 7.4),
137 mM NaCl, 2.7 mM KCl] at 197,300 g for 45 min at
4°C, conditions sufficient to sediment complexes of 165S or
larger. Pellets were suspended in 100 l of PBS, and 50-l
aliquots of each suspension were mixed with equal volumes
of 2  xample buffer plus 0.1 vol of -Me. For SDS–
polyacrylamide gel electrophoresis (SDS–PAGE) on 7.5–
10% gels (Hansen et al., 1990; Jones et al., 1990), 75-l
sample mixes, representing 13% of cell samples and 33% of
virus samples, were used. After electrophoresis and elec-
troblotting onto nitrocellulose filters, Gag proteins were
detected by immunoblotting using Hy548 (anti-M-MuLV
p12) or Hy187 (anti-M-MuLV CA) primary antibodies
(Cheesebro et al., 1983), an alkaline-phosphatase conju-
gated goat antimouse IgG secondary antibody (Promega),
and a BCIP (5-bromo-4-chloro-3-indolyl phosphate) plus
NBT (nitroblue tetrazolium)-mediated color reaction (Jones
et al., 1990) for visualization. Quantitation was accom-
plished using NIH Image 1.61 software on scanned, digi-
tized images.
Gag proteins also were detected by immunoblotting after
a variety of fractionation and crosslinking procedures. Sub-
cellular fractionation into postnuclear cytosol and mem-
brane fractions followed established methods (Hansen et al.,
1993). Fractionation of extracellular material on 20–50%
sucrose density gradients was as described previously (Han-
sen et al., 1990; Jones et al., 1990; Wang and Barklis, 1993).
For analysis of particle stabilities, 50-l virus samples were
diluted to 200 l in PBS, incubated 30 min at 4°C in the
absence or the presence of 0.5% Triton X-100, centrifuged
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at 100,000 g for 30 min at 4°C, and collected as pellet and
supernatant fractions. BMH crosslinking of Gag proteins in
particle samples was performed by treatment of samples for
60 min with 1 mM BMH (Pierce; Hansen and Barklis, 1995;
McDermott et al., 1996, 2000b). Molecular weight esti-
mates for Gag proteins and crosslink products were calcu-
lated by comparison of SDS–PAGE mobilities with the
mobilities of known size standards (Gibco, Bio–Rad).
RNase protection assays
For quantitation of cellular and particle-associated MP10
RNA levels, triplicate 10-cm plates of cells were transfected
with either MP10 alone or MP10 plus WT, A1SP, A5SP, or
HIV/Mo constructs. Three days posttransfection, pelleted
particle samples were resuspended in 50 mM Tris–HCl (pH
7.5), 5 mM EDTA, 0.1% SDS and divided into aliquots for
Gag protein quantitation by immunoblotting (see above)
and for viral RNA isolation. Viral RNA was isolated by
phenol–chloroform and chloroform extraction, followed by
ethanol precipitation (Mougel et al., 1996; Zhang and Bark-
lis, 1995, 1997), suspension in RNase-free water, and stor-
age at 80°C. Total cellular RNA samples were isolated
from guanidine thiocynate-treated cells by cesium chloride
density gradient centrifugation (Wang et al., 1993), quanti-
tated via absorbance readings at 260 nm, and stored at
80°C in RNase-free water.
The 274-nt antisense probe for RNase protection assays
protects a 214-nt fragment from full-length MP10 RNAs
and a 205-nt fragment from spliced MP10 RNAs (Barklis et
al., 1986). It was prepared using [-32P] GTP (Amersham)
in SP6 transcription reactions from EcoRI-linearized
SPMLV templates and purified by denaturing polyacryl-
amide gel electrophoresis (Barklis et al., 1986; Mougel et
al., 1996). Overnight 42°C hybridization reactions em-
ployed 1–1.5  105 cpm probe plus 20 g of cellular RNA,
viral RNA (one third of each preparation) supplemented
with 10 g of yeast tRNA, or just 10 g of yeast tRNA as
a control (Barklis et al., 1986; Mougel et al., 1996). Unpro-
tected single-stranded RNAs were digested 30 min at 30°C
with 40 g/ml of RNaseA plus 2 g/ml of RNaseT1, after
which samples were treated with 150 g/ml of proteinase K
(15 min, 37°C), cleaned by phenol–chloroform extraction
and ethanol precipitation, and fractionated on sequencing
gels (Barklis et al., 1986; Mougel et al., 1996; Wang et al.,
1993; Zhang and Barklis 1995, 1997). Protected probe frag-
ments were visualized by autoradiography and were quan-
titated using NIH Image 1.61 software after scanning and
digitization. To evaluate encapsidation specificities, ratios
of full-length to spliced MP10 RNA levels in virus particle
samples were calculated. For evaluation of encapsidation
efficiencies, particle-associated unspliced MP10 RNA lev-
els were normalized for Gag protein content, and normal-
ized values were compared with those of the WT construct
(1.0).
Immunofluorescence and electron microscopy
Immunofluorescent detection of PrGag proteins using
Hy548 (Cheesbro et al., 1983) followed the method of
Hansent et al. (1990). Transfected Cos7 cells on coverslips
were fixed 20 min in 3.7% formaldehyde in PBS, washed,
permeabilized 10 min in 0.2% Triton X-100 in PBS, incu-
bated 1 h with primary antibody, washed, incubated 1 h with
rhodamine-conjugated goat antimouse IgG secondary anti-
body (Biosource), washed, and mounted onto slides in PBS
containing 50% glycerol. Images were collected electroni-
cally on a Zeiss fluorescence microscope and were evalu-
ated for the appearance of a fluorescent patch adjacent to the
nucleus (perinuclear staining), the presence of fluorescent
spots against an otherwise black backround (punctate stain-
ing), and an increased fluorescent signal at cell edges (pe-
ripheral staining).
For EM, media were carefully removed from transfected
293T cells and were replaced with fixative [100 mM sodium
cacodylate (pH 7.2), 2.5% glutaraldehyde, 1.6% parafor-
maldehyde, 0.064% picric acid, 0.1% ruthenium red] for 30
min. After removal of fixative, cells were gently washed in
PBS, scraped into PBS, and pelleted in Eppendorf tubes.
Cell pellets were postfixed 1 h in 1% osmium tetroxide plus
0.8% potassium ferricyanide in 100 mM sodium cacodylate,
pH 7.2. After thorough rinsing in water, cells were
prestained in 4% uranyl acetate 1 h, thoroughly rinsed,
dehydrated, infiltrated overnight in 1:1 acetone:Epon 812,
infiltrated 1 h with 100% Epon 812 resin, and embedded in
the resin. After polymerization, 60- to 80-nm thin sections
were cut on a Reichert ultramicrotome, stained 5 min in lead
citrate, rinsed, poststained 30 min in uranyl acetate, rinsed,
and dried. EM was performed at 60 kV on a Philips CM120/
Biotwin equipped with a 10241024 Gatan multiscan
CCD, and images were collected at original magnifications
of 2810–11,290. For tabulation of particle morphologies,
assembling particles were defined as particles with evident
plasma membrane attachments; normal particles were de-
fined as 120- to 180-nm-diameter particles with a circle of
electron density adjacent to the particle surface; the irregu-
lar particle classification included off-sized particles, long
oval particles, lobed particles, and particles with incomplete
electron-dense rings; while tubes were defined as having an
axial ratio of 2, a width of 100–200 nm, and electron-
dense tracks adjacent to tube surfaces.
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